Starpharma Holdings (SPHR.F) Stock Overview
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SPHR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Starpharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.24 |
| 52 Week High | AU$0.29 |
| 52 Week Low | AU$0.06 |
| Beta | 0.49 |
| 1 Month Change | -16.52% |
| 3 Month Change | 12.78% |
| 1 Year Change | 222.58% |
| 3 Year Change | -39.36% |
| 5 Year Change | -85.45% |
| Change since IPO | -65.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPHR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.6% | -0.1% |
| 1Y | 222.6% | 29.1% | 13.8% |
Return vs Industry: SPHR.F exceeded the US Pharmaceuticals industry which returned 29.1% over the past year.
Return vs Market: SPHR.F exceeded the US Market which returned 13.8% over the past year.
Price Volatility
| SPHR.F volatility | |
|---|---|
| SPHR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SPHR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SPHR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 40 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
Starpharma Holdings Limited Fundamentals Summary
| SPHR.F fundamental statistics | |
|---|---|
| Market cap | US$109.07m |
| Earnings (TTM) | -US$7.01m |
| Revenue (TTM) | US$4.11m |
Is SPHR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPHR.F income statement (TTM) | |
|---|---|
| Revenue | AU$5.85m |
| Cost of Revenue | AU$9.58m |
| Gross Profit | -AU$3.73m |
| Other Expenses | AU$6.26m |
| Earnings | -AU$9.99m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | -63.74% |
| Net Profit Margin | -170.77% |
| Debt/Equity Ratio | 2.3% |
How did SPHR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 01:40 |
| End of Day Share Price | 2026/01/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Starpharma Holdings Limited is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthijs Smith | Canaccord Genuity |
| Derek Jellinek | CGS International |
| Waradana Malitha De Silva | CLSA |